Molecules to Market launches skin diagnosis system
This article was originally published in Clinica
Executive Summary
UK point-of-care specialist Molecules to Market has launched its first product, Dermadex, a computer-based skin diagnosis system in Japan, the UK and US. CEO Peter Keeling says the privately-funded company has identified areas in primary care where costs can be saved by new decision-making tools. This includes diseases with high referral rates, women's health and ageing.